Intellia Therapeutics, Inc. (NTLA) Shares Sold by Goldman Sachs Group Inc.
Goldman Sachs Group Inc. lowered its position in Intellia Therapeutics, Inc. (NASDAQ:NTLA) by 75.0% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 40,700 shares of the company’s stock after selling 122,003 shares during the period. Goldman Sachs Group Inc. owned about 0.11% of Intellia Therapeutics worth $573,000 as of its most recent filing with the SEC.
Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Vanguard Group Inc. raised its position in Intellia Therapeutics by 3.9% in the first quarter. Vanguard Group Inc. now owns 904,708 shares of the company’s stock worth $12,747,000 after buying an additional 33,925 shares in the last quarter. GMT Capital Corp bought a new position in shares of Intellia Therapeutics during the first quarter worth approximately $4,657,000. Acadian Asset Management LLC bought a new position in shares of Intellia Therapeutics during the first quarter worth approximately $1,355,000. Paulson & CO. Inc. bought a new position in shares of Intellia Therapeutics during the first quarter worth approximately $1,107,000. Finally, Geode Capital Management LLC raised its position in shares of Intellia Therapeutics by 6.0% in the first quarter. Geode Capital Management LLC now owns 76,095 shares of the company’s stock worth $1,072,000 after buying an additional 4,291 shares in the last quarter. 47.20% of the stock is owned by hedge funds and other institutional investors.
Shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA) traded down 4.35% during mid-day trading on Friday, reaching $15.16. 334,538 shares of the company’s stock traded hands. Intellia Therapeutics, Inc. has a 12 month low of $10.83 and a 12 month high of $24.90. The firm has a 50 day moving average price of $16.46 and a 200-day moving average price of $14.44. The stock’s market cap is $547.46 million.
Intellia Therapeutics (NASDAQ:NTLA) last issued its earnings results on Thursday, August 3rd. The company reported ($0.45) EPS for the quarter, missing the consensus estimate of ($0.42) by $0.03. The firm had revenue of $5.90 million during the quarter, compared to analyst estimates of $5.83 million. Intellia Therapeutics had a negative net margin of 204.48% and a negative return on equity of 22.70%. The business’s revenue was up 40.5% on a year-over-year basis. On average, analysts predict that Intellia Therapeutics, Inc. will post ($1.74) earnings per share for the current fiscal year.
TRADEMARK VIOLATION WARNING: This piece of content was reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this piece of content on another publication, it was stolen and republished in violation of U.S. and international trademark and copyright laws. The correct version of this piece of content can be viewed at https://www.thecerbatgem.com/2017/08/20/intellia-therapeutics-inc-ntla-shares-sold-by-goldman-sachs-group-inc.html.
A number of research analysts have recently commented on the stock. Credit Suisse Group set a $24.00 price objective on shares of Intellia Therapeutics and gave the company a “buy” rating in a research report on Saturday, June 3rd. TheStreet raised shares of Intellia Therapeutics from a “d+” rating to a “c-” rating in a research report on Thursday, July 6th. Oppenheimer Holdings, Inc. assumed coverage on shares of Intellia Therapeutics in a research report on Tuesday, July 18th. They issued a “market perform” rating for the company. Chardan Capital reissued a “buy” rating and issued a $20.00 price target (up previously from $19.00) on shares of Intellia Therapeutics in a research report on Wednesday, August 2nd. Finally, Jefferies Group LLC reissued a “buy” rating and issued a $36.00 price target on shares of Intellia Therapeutics in a research report on Thursday, June 22nd. Three research analysts have rated the stock with a hold rating and six have given a buy rating to the stock. The company presently has a consensus rating of “Buy” and an average target price of $24.83.
In related news, major shareholder Venture Fund Ix L.P. Atlas sold 150,000 shares of the company’s stock in a transaction that occurred on Tuesday, July 11th. The shares were sold at an average price of $16.24, for a total transaction of $2,436,000.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. 12.80% of the stock is owned by corporate insiders.
About Intellia Therapeutics
Intellia Therapeutics, Inc is a genome editing company. The Company is focused on developing therapeutics utilizing a biological tool known as CRISPR/Cas9. The CRISPR/Cas9 genome editing system includes two components: the Cas9 protein and the guide RNA sequence. The Cas9 protein acts like a pair of molecular scissors that initiates the natural cellular repair process to knockout, repair or insert a gene.
Receive News & Stock Ratings for Intellia Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intellia Therapeutics Inc. and related stocks with our FREE daily email newsletter.